MTRI

Mentari Therapeutics Inc

16.00

Nov 09 • 3:59 PM ET +0.44 (2.83%)

16.00

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Drug Manufacturers - Specialty & Generic USA Nano NASD

Peers: IXHL CRDL OPTH SUPN ARTL BIVI AXSM AVXL TNXP EYPT

Scroll to Statements

Index	-
Market Cap	8.79M
Enterprise Value	7.66M
Income	-13.60M
Sales	0.82M
Book/sh	-0.22
Cash/sh	2.06
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	Nov 17, 2008

P/E	-
Forward P/E	-
PEG	-
P/S	10.72
P/B	-
P/C	7.78
P/FCF	-
EV/EBITDA	-
EV/Sales	9.34
Quick Ratio	0.50
Current Ratio	0.50
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / No

EPS (ttm)	-3.11
EPS next Y	-1.89
EPS next Q	-
EPS this Y	-25.40%
EPS next Y	-19.62%
EPS next 5Y	-19.13%
EPS past 3/5Y	63.64% 66.67%
Sales past 3/5Y	- -
EPS Y/Y TTM	55.05%
Sales Y/Y TTM	-82.91%
EPS Q/Q	2.43%
Sales Q/Q	-100.00%
Earnings	Sep 09 AMC
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	36.84%
Inst Trans	-
ROA	-158.97%
ROE	-224.38%
ROIC	-
Gross Margin	-71.90%
Oper. Margin	-1238.62%
Profit Margin	-1657.72%
SMA20	7.87%
SMA50	14.30%
SMA200	31.49%
Trades

Shs Outstand	5.49M
Shs Float	-
Short Float	-
Short Ratio	0.09
Short Interest	0.00M
52W High	23.30 -31.33%
52W Low	5.75 178.26%
Volatility	21.57% 9.77%
ATR (14)	1.70
RSI (14)	55.93
Beta	0.97
Rel Volume	7.01
Avg Volume	7.75K
Volume	54,315

Perf Week	-1.84%
Perf Month	17.65%
Perf Quarter	9.59%
Perf Half Y	157.65%
Perf YTD	50.94%
Perf Year	0.00%
Perf 3Y	-78.89%
Perf 5Y	-99.77%
Perf 10Y	-99.93%
Recom	1.00
Target Price	42.00
Prev Close	15.56
Price	16.00
Change %	2.83%

Today 08:00AM	Mentari Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
01:16AM	Fox-Rokus $22B Deal, A New Nasdaq Biotech And A $25B Chemicals Tie-Up: Deals Investors Are Watching (Stocktwits)
Nov-06-26 04:05PM	InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics (PR Newswire) +17.79%
Nov-05-26 04:01PM	InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI" (Newsfile Corp.) -24.51%
Nov-04-26 04:51PM	InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation (Newsfile)
07:30AM	Loading…
Nov-03-26 07:30AM	InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update (Newsfile)
Nov-02-26 04:15PM	InMed Announces Share Consolidation in Connection with Proposed Merger (Newsfile Corp.)
Oct-26-26 08:01PM	InMed Announces CVR Distribution Record Date in Connection with Proposed Merger (Newsfile Corp.) +10.42%
Oct-14-26 09:47PM	How Much Downside Is Left In Liquidia Stock? (Trefis)
Sep-18-26 04:45PM	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance (Newsfile)
Sep-09-26 04:30PM	InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update (Newsfile)
Jul-22-26 07:00AM	Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline (PR Newswire) +7.79%
Jul-06-26 07:15PM	Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders? (PR Newswire)
06:20PM	InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4 (Newsfile)
Jun-12-26 11:51AM	Are GBTG, INM, CZR, TMHC Obtaining Fair Deals for their Shareholders? (PR Newswire)
05:00PM	Loading…
Jun-04-26 05:00PM	InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements (Newsfile)
May-28-26 06:57PM	Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders? (PR Newswire) -6.55%
May-19-26 10:37AM	InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM) (InvestorsHub) +135.05%
08:00AM	InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies (PR Newswire)
07:19AM	A migraine drugmaker heads to the public markets through reverse merger (BioPharma Dive)
06:00AM	InMed Pharmaceuticals Amends Preferred Investment Options (Newsfile Corp.)
May-06-26 06:00PM	InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update (Newsfile)
Apr-27-26 05:30PM	InMed Pharmaceuticals Amends Preferred Investment Options (Newsfile) -5.03%
Mar-27-26 05:05PM	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance (Newsfile) -6.22%
Mar-23-26 07:30AM	InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program (Newsfile) -6.92%
Mar-18-26 08:00AM	Sidoti Events, LLC's March Small-Cap Virtual Conference (ACCESSWIRE)
Mar-09-26 07:30AM	InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial (Newsfile)
Mar-06-26 05:04PM	InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline (Newsfile)
Feb-11-26 05:23PM	InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update (Newsfile) -10.09%
Dec-17-25 08:00PM	InMed Announces Results of 2025 Annual General and Special Meeting (Newsfile) -8.75% +7.50%
05:30PM	Loading…
Dec-12-25 05:30PM	InMed Provides Update on BayMedica Commercial Business (Newsfile) -16.08%
Nov-18-25 07:30AM	InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901 (Newsfile) -11.52%
Nov-06-25 04:51PM	InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update (Newsfile) -6.16%
Oct-16-25 08:30AM	InMed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors (Newsfile) -5.45%
Oct-09-25 08:30AM	InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors (Newsfile)
Sep-24-25 08:45AM	InMed Pharmaceuticals reports FY25 EPS ($8.36) vs ($20.14) last year (TipRanks)
Sep-23-25 08:30AM	InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update (Newsfile) -5.73%
Sep-05-25 01:33PM	InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (Newsfile)
Jul-28-25 07:00AM	InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025 (Newsfile)
Jun-27-25 07:00AM	InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules (Newsfile)
Jun-25-25 08:00AM	InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules (Newsfile)
Jun-24-25 07:00AM	InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study (Newsfile) +57.96%
Jun-13-25 04:30PM	InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA (Newsfile) -5.95% -6.32%
May-12-25 06:00PM	InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update (Newsfile) +14.91%
Feb-12-25 06:54PM	InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update (Newsfile)
Feb-03-25 07:30AM	InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration (Newsfile)
Jan-22-25 07:30AM	InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds (Newsfile) -20.79%
Jan-21-25 07:30AM	InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study (Newsfile)
Dec-18-24 08:00PM	InMed Announces Results of 2024 Annual General Meeting (Newsfile) -16.18%
Dec-17-24 04:56PM	InMed Enters Into Standby Equity Purchase Agreement (Newsfile)
Nov-19-24 07:30AM	InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System (Newsfile)
Nov-14-24 04:45PM	InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update (Newsfile) +9.29% -15.73%
Nov-08-24 04:44PM	InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules (Newsfile)
Nov-05-24 08:30AM	InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules (Newsfile) -7.41%
Oct-28-24 07:30AM	InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease (Newsfile) +6.63%
Oct-24-24 08:00AM	InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease (Newsfile)
Oct-22-24 08:00AM	InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board (Newsfile) +10.00%
Sep-30-24 08:00AM	InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update (Newsfile)
Sep-20-24 04:30PM	InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date (Newsfile) -12.16%
Aug-21-24 07:30AM	InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents (Newsfile)
Aug-20-24 07:30AM	InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease (Newsfile) +191.35%
Jul-30-24 08:00AM	InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data (Newsfile) -17.59%
Jun-28-24 06:00AM	7 F-Rated Growth Stocks to Avoid Right Now: June 2024 (InvestorPlace)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-10-24 05:18PM	InMed to Present at the Emerging Growth Conference (Newsfile)
Jun-06-24 07:38AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -15.51%
May-14-24 10:53PM	INM Stock Earnings: InMed Pharmaceuticals Reported Results for Q3 2024 (InvestorPlace)
08:30AM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update (Newsfile)
Apr-18-24 08:00AM	InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board (Newsfile)
Apr-16-24 08:00AM	InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration (Newsfile)
Apr-04-24 08:00AM	InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies (Newsfile)
Mar-20-24 08:30AM	InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance (Newsfile)
Feb-13-24 05:41PM	InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update (Newsfile)
Feb-09-24 08:00AM	InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer (Newsfile)
Jan-18-24 04:41PM	InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET (Newsfile)
Jan-16-24 08:00AM	InMed Pharmaceuticals Provides Business Update and Milestones for 2024 (Newsfile)
Dec-19-23 06:03PM	InMed Announces Results of 2023 Annual General Meeting (Newsfile) +5.54%
Nov-29-23 08:00AM	InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration (Newsfile) +21.74%
Nov-14-23 08:04AM	InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update (Newsfile)
Nov-02-23 08:00AM	InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 (Newsfile)
Oct-26-23 07:15PM	InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules (Newsfile) -9.53% -15.93%
Oct-25-23 09:00AM	Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today? (InvestorPlace) -24.18%
Oct-24-23 04:38PM	InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules (Newsfile) +70.53%
07:30AM	InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies (Newsfile)
Sep-29-23 01:21PM	InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update (Newsfile)
Sep-22-23 06:15PM	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance (Newsfile)
Sep-07-23 08:30AM	InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference (Newsfile)
Jul-21-23 07:30AM	InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET (Newsfile) +6.05%
Jul-20-23 07:30AM	InMed Provides Update on BayMedica Rare Cannabinoid Business (Newsfile) +5.32%
Jun-22-23 02:28PM	Why Are InMed Pharmaceuticals Stock Trading Lower Today (Benzinga) -13.57%
07:30AM	InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa (Newsfile)
Jun-01-23 07:30AM	InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting (Newsfile)
May-24-23 06:51PM	InMed to Participate in Upcoming Virtual Investor Events (Newsfile)
May-18-23 05:00PM	InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET (Newsfile) +20.87%
May-15-23 12:33PM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update (Newsfile)
Mar-28-23 07:30AM	InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa (Newsfile) -9.45%
Mar-13-23 07:30AM	InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions (Newsfile) +7.62%
Mar-10-23 08:35AM	Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-07-23 08:35AM	Life Sciences Virtual Investor Forum Agenda Announced for March 9th (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ADAR1 Capital Management, LLC	10% Owner	Nov 05 '26	Buy	13.10	2,640	34,572	98,297	Nov 09 08:18 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 23 '26	Buy	1.32	4	5	956,584	Oct 27 02:13 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 19 '26	Buy	1.32	1,086	1,434	956,580	Oct 20 05:31 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 16 '26	Buy	1.32	1	1	955,494	Oct 20 05:31 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 14 '26	Buy	1.33	8,021	10,668	954,509	Oct 15 04:39 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 15 '26	Buy	1.32	984	1,301	955,493	Oct 15 04:39 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 13 '26	Buy	1.33	564	750	946,488	Oct 15 04:39 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 06 '26	Buy	1.33	5,601	7,436	940,622	Oct 08 06:27 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 07 '26	Buy	1.33	3,046	4,051	943,668	Oct 08 06:27 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 08 '26	Buy	1.33	2,256	2,997	945,924	Oct 08 06:27 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 05 '26	Buy	1.33	18,182	24,182	935,021	Oct 05 05:11 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 01 '26	Buy	1.33	16,431	21,850	908,532	Oct 05 05:11 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 02 '26	Buy	1.33	8,307	11,048	916,839	Oct 05 05:11 PM
ADAR1 Capital Management, LLC	10% Owner	Sep 15 '26	Buy	1.30	54,256	70,446	883,761	Sep 16 06:58 PM
ADAR1 Capital Management, LLC	10% Owner	Sep 14 '26	Buy	1.29	28,505	36,880	829,505	Sep 16 06:58 PM
ADAR1 Capital Management, LLC	10% Owner	Sep 16 '26	Buy	1.29	8,340	10,750	892,101	Sep 16 06:58 PM
ADAR1 Capital Management, LLC	10% Owner	Jul 15 '26	Buy	1.55	1,000	1,555	801,000	Jul 17 07:29 PM
Vivo Opportunity, LLC	10% Owner	Jul 15 '26	Buy	1.55	15,150	23,482	743,038	Jul 16 09:58 PM
Vivo Opportunity, LLC	10% Owner	Jul 14 '26	Buy	1.55	5,375	8,331	729,277	Jul 16 09:58 PM
Vivo Opportunity, LLC	10% Owner	Jul 16 '26	Buy	1.55	21	33	743,057	Jul 16 09:58 PM
Vivo Opportunity, LLC	10% Owner	Jul 01 '26	Buy	1.55	4,344	6,733	722,935	Jul 02 07:02 PM
Vivo Opportunity, LLC	10% Owner	Jul 02 '26	Buy	1.55	1,607	2,491	724,395	Jul 02 07:02 PM
Vivo Opportunity, LLC	10% Owner	Jun 30 '26	Buy	1.54	600	924	718,989	Jul 02 07:02 PM
Vivo Opportunity, LLC	10% Owner	May 20 '26	Buy	1.56	56,210	87,688	543,129	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 05 '26	Buy	1.57	55,011	86,367	688,926	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	May 21 '26	Buy	1.69	34,000	57,460	574,011	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 08 '26	Buy	1.52	32,500	49,400	718,444	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 02 '26	Buy	1.52	22,848	34,729	625,766	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	May 29 '26	Buy	1.57	17,796	27,940	590,175	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 01 '26	Buy	1.55	16,336	25,321	605,013	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 03 '26	Buy	1.55	7,783	12,064	632,835	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 04 '26	Buy	1.57	6,743	10,587	638,960	Jun 10 09:14 PM
ADAR1 Capital Management, LLC	10% Owner	May 19 '26	Buy	1.54	468,551	721,548	800,000	May 21 05:08 PM

Mentari Therapeutics, Inc. is a biotechnology company, which engages in developing therapies for migraine prevention. Its portfolio includes MT-001 and MT-002. The company was founded on June 13, 2025 and is headquartered in Waltham, MA.

M.I.B.Mr. Eric A. Adams B.S. Chem.

CFO & Corporate SecretaryMs. N. Netta Jagpal

Chief Operating OfficerMr. Michael Woudenberg P.Eng.

Senior Vice President of Preclinical Research & DevelopmentDr. Eric Chih-Hsien Hsu Ph.D.

Ph.D.Dr. Sazzad Hossain M.Sc.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MTRI

Mentari Therapeutics Inc

Upgrade your Finviz experience